BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12548357)

  • 1. Magnetic resonance relaxometry in Parkinson's disease.
    Mondino F; Filippi P; Magliola U; Duca S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S87-8. PubMed ID: 12548357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
    Martin WR; Wieler M; Gee M
    Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.
    Michaeli S; Oz G; Sorce DJ; Garwood M; Ugurbil K; Majestic S; Tuite P
    Mov Disord; 2007 Feb; 22(3):334-40. PubMed ID: 17149719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibility-weighted imaging in detecting brain iron accumulation of Parkinson's disease].
    Huang XM; Sun B; Xue YJ; Duan Q
    Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(43):3054-8. PubMed ID: 21211325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
    Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
    J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
    Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
    Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging and spectroscopy in Parkinson's disease.
    Martin WR
    Adv Neurol; 2001; 86():197-203. PubMed ID: 11553978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
    Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
    Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image].
    Moriwaka F; Tashiro K; Itoh K; Hamada T; Miyasaka K
    Rinsho Shinkeigaku; 1992 Jan; 32(1):8-12. PubMed ID: 1628441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.
    Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE
    Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron histochemistry of the substantia nigra in Parkinson's disease.
    Morris CM; Edwardson JA
    Neurodegeneration; 1994 Dec; 3(4):277-82. PubMed ID: 7842298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
    Geng DY; Li YX; Zee CS
    Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
    O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
    Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism.
    Brar S; Henderson D; Schenck J; Zimmerman EA
    Arch Neurol; 2009 Mar; 66(3):371-4. PubMed ID: 19273756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative estimation of regional brain iron with magnetic resonance imaging.
    Martin WR
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S215-8. PubMed ID: 20082994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.